{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:16:36Z","timestamp":1795043796549,"version":"4.10.2"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005626","name":"Universit\u00e4t Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005626","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian cancer is the most lethal gynecologic cancer. This study explores differences in observed survival rates among ovarian cancer patients treated in certified versus non-certified hospitals in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study used data from German statutory health insurance (SHI) funds and clinical cancer registries (CCRs), including 20,794 insured and 4,493 registry patients diagnosed with a malignant ovarian neoplasm (ICD-10-GM code C56) from 2009 to 2017. Patients were categorized based on whether they received primary treatment at hospitals certified as ovarian cancer centers by the German Cancer Society (DKG) or at non-certified hospitals. Survival analyses were conducted using Kaplan\u2013Meier and multivariable Cox regression methods. Adjustments were performed for age, year of diagnosis, International Union Against Cancer (UICC) stage, grade, lymphatic and venous invasion, year of index treatment, distant metastasis, Elixhauser comorbidities, and hospital criteria where available in the data source used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After adjustment for various confounders, treatment in certified centers was associated with a lower mortality risk, corresponding to a hazard ratio (HR) of 0.883 (95% CI 0.824\u20130.948;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) in the SHI data. In the CCR data a non-significant HR of 0.964 was observed (95% CI 0.867\u20131.071;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.490). Among patients in the CCR cohort diagnosed with UICC stage I\u2013III disease, receiving treatment at certified centers was associated with improved survival outcomes (HR 0.825, 95% CI 0.708\u20130.961;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment in DKG-certified centers is associated with better survival in ovarian cancer patients, especially in earlier stages. Certification status may be a relevant factor when choosing a treatment facility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (identifier: NCT04334239). Retrospectively registered on 6 April 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13048-025-01843-8","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:31:47Z","timestamp":1762263107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of survival in ovarian cancer patients following treatment in certified gynecologic oncology centers and non-certified hospitals: a German retrospective cohort study (WiZen)"],"prefix":"10.1186","volume":"18","author":[{"given":"Judith","family":"Hansinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Schoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinzenz","family":"V\u00f6lkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bierbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Bobeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"R\u00f6\u00dfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Dr\u00f6ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ruhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"G\u00fcnster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees","family":"Kleihues-van Tol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Kast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Papathemelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Ortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Klinkhammer-Schalke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"3","key":"1843_CR1","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/S2589-7500(23)00245-5","volume":"6","author":"G Cai","year":"2024","unstructured":"Cai G, Huang F, Gao Y, Li X, Chi J, Xie J, et al. Artificial intelligence-based models enabling accurate diagnosis of ovarian cancer using laboratory tests in china: a multicentre, retrospective cohort study. Lancet Digit Health. 2024;6(3):e176\u201386.","journal-title":"Lancet Digit Health"},{"issue":"6","key":"1843_CR2","first-page":"561","volume":"91","author":"SM Penny","year":"2020","unstructured":"Penny SM. Ovarian cancer: an overview. Radiol Technol. 2020;91(6):561\u201375.","journal-title":"Radiol Technol"},{"issue":"5","key":"1843_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1843_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151\u20136.","journal-title":"Semin Oncol Nurs"},{"key":"1843_CR5","unstructured":"Robert Koch-Institut. Zentrum f\u00fcr Krebsregisterdaten. 2024 [cited 2024 Jun 11]. Eierstockkrebs (Ovarialkarzinom). Available from: https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Eierstockkrebs\/eierstockkrebs_node.html"},{"key":"1843_CR6","first-page":"310","volume-title":"International union against Cancer, editors. TNM classification of malignant tumours","author":"LH Sobin","year":"2010","unstructured":"Sobin LH. International union against Cancer, editors. TNM classification of malignant tumours. 7 ed. Oxford: Wiley-Blackwell; 2010. p. 310.","edition":"7"},{"key":"1843_CR7","unstructured":"Krebsforschungszentrum. Eierstockkrebs (Ovarialkarzinom) [Internet]. 2024 [cited 2024 Jun 11]. Available from: https:\/\/www.krebsinformationsdienst.de\/tumorarten\/eierstockkrebs.php"},{"key":"1843_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/341723","volume":"2015","author":"A Toss","year":"2015","unstructured":"Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. BioMed Res Int. 2015;2015:341723.","journal-title":"BioMed Res Int"},{"issue":"22","key":"1843_CR9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS. Effect of screening on ovarian cancer mortality: the Prostate, Lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295.","journal-title":"JAMA"},{"key":"1843_CR10","doi-asserted-by":"publisher","unstructured":"Burges A, Schmalfeldt B, Ovarian, Cancer. Deutsches \u00c4rzteblatt international [Internet]. 2011 Sep 23 [cited 2024 Jun 11]; Available from: https:\/\/www.aerzteblatt.de\/https:\/\/doi.org\/10.3238\/arztebl.2011.0635","DOI":"10.3238\/arztebl.2011.0635"},{"key":"1843_CR11","unstructured":"S3-Leitlinie. Leitlinienprogramm Onkologie: Supportive Therapie [Internet]. 2024 [cited 2024 Jun 11]. Available from: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/supportive-therapie\/"},{"issue":"9","key":"1843_CR12","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","volume":"4","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239\u201357.","journal-title":"Nat Cancer"},{"issue":"1","key":"1843_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-024-01580-4","volume":"18","author":"D Chen","year":"2025","unstructured":"Chen D, Tan Y, Chen T, Wang Q, Yan Y, Zhao X, et al. Sempervirine inhibits proliferation, invasion and metastasis of ovarian cancer cells and induces ultrastructural changes in vivo. J Ovarian Res. 2025;18(1):17.","journal-title":"J Ovarian Res"},{"issue":"7","key":"1843_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1136\/ijgc-2022-004233","volume":"33","author":"P Wimberger","year":"2023","unstructured":"Wimberger P, Pfisterer J, du Bois A, Hilpert F, Kerkmann M, Sehouli J, et al. Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO study group. Int J Gynecol Cancer. 2023;33(7):1083\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1843_CR15","first-page":"182","volume":"61","author":"P Harter","year":"2020","unstructured":"Harter P, Pfisterer J, Hilpert F, Sehouli J, Lamparter C, Kerkmann M, et al. Therapiequalit\u00e4t des fortgeschrittenen ovarialkarzinoms in Deutschland. Frauenarzt. 2020;61(3):182\u20138.","journal-title":"Frauenarzt"},{"key":"1843_CR16","unstructured":"Schoffer O, R\u00f6\u00dfler M, Bierbaum V, Bobeth C, Gerken M, Kleihues-van Tol K et al. Ergebnisbericht. Innovationsfonds GBA. https:\/\/innovationsfonds.g-ba.de\/downloads\/beschluss-dokumente\/268\/2022-10-17_WiZen_Ergebnisbericht.pdf [Internet]. 2022 Oct [cited 2024 Jun 14]. Available from: https:\/\/innovationsfonds.g-ba.de\/downloads\/beschluss-dokumente\/268\/2022-10-17_WiZen_Ergebnisbericht.pdf"},{"key":"1843_CR17","unstructured":"OnkoZert O. 2024 [cited 2024 Jun 13]. Gyn\u00e4kologische Krebszentren. Available from: https:\/\/www.onkozert.de\/system\/gyn\/"},{"issue":"10","key":"1843_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1055\/a-1869-2060","volume":"84","author":"J Hansinger","year":"2024","unstructured":"Hansinger J, V\u00f6lkel V, Gerken M, Schoffer O, Wimberger P, Bierbaum V, et al. Endometrial cancer - Long-term survival in certified cancer centers and non-certified hospitals: comparative analysis based on a large German retrospective cohort study (WiZen). Geburtshilfe Frauenheilkd. 2024;84(10):979\u201388.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"02","key":"1843_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1055\/a-1869-1772","volume":"84","author":"O Schoffer","year":"2024","unstructured":"Schoffer O, Wimberger P, Gerken M, Bierbaum V, Bobeth C, R\u00f6\u00dfler M, et al. Treatment in certified breast cancer centers improves chances of survival of patients with breast cancer: evidence based on health care data from the WiZen study. Geburtshilfe Frauenheilkd. 2024;84(02):153\u201363.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"1843_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-03262-9","volume":"22","author":"V Bierbaum","year":"2024","unstructured":"Bierbaum V, Bobeth C, Roessler M, Gerken M, van Tol KK, Reissfelder C, et al. Treatment in certified cancer centers is related to better survival in patients with colon and rectal cancer: evidence from a large German cohort study. World J Surg Oncol. 2024;22(1):11.","journal-title":"World J Surg Oncol"},{"issue":"18","key":"1843_CR21","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.3390\/cancers15184568","volume":"15","author":"V V\u00f6lkel","year":"2023","unstructured":"V\u00f6lkel V, Gerken M, Kleihues-van Tol K, Schoffer O, Bierbaum V, Bobeth C, et al. Treatment of colorectal cancer in certified centers: results of a large German registry study focusing on Long-Term survival. Cancers (Basel). 2023;15(18):4568.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1843_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/s12885-022-09731-w","volume":"22","author":"M Roessler","year":"2022","unstructured":"Roessler M, Schmitt J, Bobeth C, Gerken M, Kleihues-van Tol K, Reissfelder C, et al. Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study. BMC Cancer. 2022;22(1):621.","journal-title":"BMC Cancer"},{"key":"1843_CR23","unstructured":"AOK, Presse P. 2024 [cited 2024 Jun 14]. Zahlen und Fakten in der gesetzlichen Krankenversicherung. Available from: https:\/\/www.aok.de\/pp\/zahlen-und-fakten\/"},{"key":"1843_CR24","unstructured":"Deutsche Gesellschaft f\u00fcr Epidemiologie. Good Practice in Secondary Data Analysis. Revision after Fundamental Reworking. [Internet]. 2024. Available from: https:\/\/www.dgepi.de\/assets\/Leitlinien-und-Empfehlungen\/Practice-in-Secondary-Data-Analysis.pdf"},{"key":"1843_CR25","doi-asserted-by":"publisher","unstructured":"O\u2019Quigley J. Survival Analysis, Proportional and Non-Proportional Hazards Regression [Internet]. London: Springer; 2021. Available from: https:\/\/doi.org\/10.1007\/978-3-030-33439-0","DOI":"10.1007\/978-3-030-33439-0"},{"issue":"1","key":"1843_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"issue":"11","key":"1843_CR27","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1177\/0962280220921889","volume":"29","author":"TA Balan","year":"2020","unstructured":"Balan TA, Putter H. A tutorial on frailty models. Stat Methods Med Res. 2020;29(11):3424\u201354.","journal-title":"Stat Methods Med Res"},{"key":"1843_CR28","unstructured":"Regierungskommission f\u00fcr eine moderne und bedarfsgerechte Krankenhausversorgung. Verbesserung von Qualit\u00e4t und Sicherheit der Gesundheitsversorgung. Potenzialanalyse anhand exemplarischer Erkrankungen. [Internet]. 2023 Jul [cited 2024 Aug 28] pp. 1\u201343. Report No.: 5. Available from: https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/K\/Krankenhausreform\/5_Stellungnahme_Potenzialanalyse_bf_Version_1.1.pdf"},{"issue":"1","key":"1843_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ygyno.2015.04.025","volume":"138","author":"DI Shalowitz","year":"2015","unstructured":"Shalowitz DI, Vinograd AM, Giuntoli RL. Geographic access to gynecologic cancer care in the United States. Gynecol Oncol. 2015;138(1):115\u201320.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1843_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ygyno.2016.07.004","volume":"142","author":"GD Aletti","year":"2016","unstructured":"Aletti GD, Cliby WA. Time for centralizing patients with ovarian cancer: what are we waiting for? Gynecol Oncol. 2016;142(2):209\u201310.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1843_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1349-7006.2004.tb02208.x","volume":"95","author":"A Ioka","year":"2004","unstructured":"Ioka A, Tsukuma H, Ajiki W, Oshima A. Influence of hospital procedure volume on ovarian cancer survival in Japan, a country with low incidence of ovarian cancer. Cancer Sci. 2004;95(3):233\u20137.","journal-title":"Cancer Sci"},{"issue":"2","key":"1843_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2009.07.011","volume":"115","author":"S Kumpulainen","year":"2009","unstructured":"Kumpulainen S, Sankila R, Leminen A, Kuoppala T, Komulainen M, Puistola U, et al. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer \u2014 a prospective nation-wide study in Finland. Gynecol Oncol. 2009;115(2):199\u2013203.","journal-title":"Gynecol Oncol"},{"issue":"S1","key":"1843_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1525-1438.2006.00319.x","volume":"16","author":"T Paulsen","year":"2006","unstructured":"Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trop\u00e9 C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16(S1):11\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1843_CR34","first-page":"499","volume":"102","author":"S Tingulstad","year":"2003","unstructured":"Tingulstad S. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol. 2003;102(3):499\u2013505.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"1843_CR35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ygyno.2008.09.036","volume":"112","author":"A Du Bois","year":"2009","unstructured":"Du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol. 2009;112(2):422\u201336.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"1843_CR36","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/cncr.22604","volume":"109","author":"BA Goff","year":"2007","unstructured":"Goff BA, Matthews BJ, Larson EH, Andrilla CHA, Wynn M, Lishner DM, et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer. 2007;109(10):2031\u201342.","journal-title":"Cancer"},{"issue":"3","key":"1843_CR37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ygyno.2010.05.025","volume":"118","author":"RE Bristow","year":"2010","unstructured":"Bristow RE, Palis BE, Chi DS, Cliby WA. The national cancer database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118(3):262\u20137.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1843_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ygyno.2016.05.025","volume":"142","author":"P Dahm-K\u00e4hler","year":"2016","unstructured":"Dahm-K\u00e4hler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - a population-based cohort study. Gynecol Oncol. 2016;142(2):211\u20136.","journal-title":"Gynecol Oncol"},{"key":"1843_CR39","doi-asserted-by":"crossref","unstructured":"Cibula D, Verheijen R, Lopes A, Amant F, Beller U, Colombo N, et al. Training in bowel and upper abdominal surgery in gynaecological oncology: European society of gynecological oncology (ESGO) statement. Int J Gynecol Cancer. 2011;21(7):1264\u20135.","DOI":"10.1097\/IGC.0b013e3182208141"},{"issue":"1","key":"1843_CR40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ijgc-2023-004401","volume":"34","author":"M Luyckx","year":"2023","unstructured":"Luyckx M, Jouret M, Sawadogo K, Waterkeyn M, Grandjean F, Van Gossum JP, et al. Centralizing surgery for ovarian cancer in a \u2018non-centralizing\u2019 country (Belgium): the UNGO (UCLouvain network of gynaecological Oncology) experience. Int J Gynecol Cancer. 2023;34(1):106\u201312.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1843_CR41","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ygyno.2016.04.012","volume":"141","author":"FA Eggink","year":"2016","unstructured":"Eggink FA, Mom CH, Kruitwagen RF, Reyners AK, Van Driel WJ, Massuger LF, et al. Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands. Gynecol Oncol. 2016;141(3):524\u201330.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1843_CR42","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/intqhc\/mzx107","volume":"29","author":"FA Eggink","year":"2017","unstructured":"Eggink FA, Vermue MC, Van der Spek C, Arts HJ, Apperloo MJ, Nijman HW, et al. The impact of centralization of services on treatment delay in ovarian cancer: a study on process quality. Int J Qual Health Care. 2017;29(6):810\u20136.","journal-title":"Int J Qual Health Care"},{"issue":"3","key":"1843_CR43","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.ygyno.2015.03.003","volume":"138","author":"J Butler","year":"2015","unstructured":"Butler J, Gildea C, Poole J, Meechan D, Nordin A. Specialist surgery for ovarian cancer in England. Gynecol Oncol. 2015;138(3):700\u20136.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1843_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1023-4","volume":"16","author":"T Kennedy-Martin","year":"2015","unstructured":"Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16(1):495.","journal-title":"Trials"},{"issue":"10329","key":"1843_CR45","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0140-6736(22)00176-3","volume":"399","author":"F Habibzadeh","year":"2022","unstructured":"Habibzadeh F. Disparity in the selection of patients in clinical trials. Lancet. 2022;399(10329):1048.","journal-title":"Lancet"},{"issue":"5","key":"1843_CR46","first-page":"295","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295\u2013300.","journal-title":"Proc R Soc Med"},{"issue":"S 04","key":"1843_CR47","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1055\/a-2350-6435","volume":"86","author":"H Pfaff","year":"2024","unstructured":"Pfaff H, Schmitt J. Shifting from theoretical best evidence to practical best evidence: an approach to overcome structural conservatism of evidence-based medicine and health policy. Gesundheitswesen. 2024;86(S 04):S239\u201350.","journal-title":"Gesundheitswesen"},{"key":"1843_CR48","unstructured":"Zentrum f\u00fcr Krebsregisterdaten (RKI), GEKID. Krebs in Deutschland f\u00fcr 2017\/2018. Robert Koch-Institut. 2021 Berlin. Report No.: 13.Ausgabe."},{"issue":"1","key":"1843_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","volume":"15","author":"R De Angelis","year":"2014","unstructured":"De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE-5\u2014a population-based study. Lancet Oncol. 2014;15(1):23\u201334.","journal-title":"Lancet Oncol"},{"key":"1843_CR50","unstructured":"Deutsches Krebsregister e.V. (DKR). DKR-L\u00e4nderatlas [Internet]. [cited 2024 Oct 23]. Available from: https:\/\/www.dkr.de\/dkr-atlas\/index.html#\/de"},{"key":"1843_CR51","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ygyno.2024.04.002","volume":"186","author":"MD Algera","year":"2024","unstructured":"Algera MD, van Driel WJ, Slangen BFM, Wouters MWJM, Kruitwagen RFPM, participants of the Dutch Gynecological Oncology Audit Collaborator Group. Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch gynecological oncology audit. Gynecol Oncol. 2024;186:144\u201353.","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01843-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:04:03Z","timestamp":1762308243000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01843-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01843-8","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The WiZen study received approval from the ethics commission of the TU Dresden (approval number: EK95022019). All data processing and analyses were conducted in compliance with the Declaration of Helsinki and the General Data Protection Regulation of the European Union.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OS, VB, CB, and JS work in a university hospital with certified cancer centers, where MR also worked previously. They received grants from the Innovation Fund of the Federal Joint Committee when carrying out the study. Outside of the submitted work, JS received institutional grants for investigator-initiated research from the G-BA, the BMG, BMBF, the EU, the German Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer. He also took part in advisory board meetings as a paid consultant for Sanofi, Lilly, and the ALK. Outside of the submitted work, OS was a paid consultant for Novartis. He is also a member of the certification committee \u201cSkin Cancer Centers\u201d of the German Cancer Society and a member of the panel of experts for the project \u201cResearch into criteria to evaluate certificates and quality seals in accordance with Sec. 137a para. 3 sentence 2 No. 7 SGB V\u201d for the Institute for Quality Assurance and Transparency in Healthcare (IQTIG). PW heads the DKG-certified Breast and Gynecological Cancer Center at the university hospital of the TU Dresden and is an additional member of the Board of Directors of NCT Dresden. PW receives institutional grants for investigator-initiated research from the DFG, Krebshilfe, S\u00e4chsische Aufbaubank (SAB), Gyn\u00e4ko-Onkologische Forschungsstiftung, Amgen, AstraZeneca, MSD, Novartis, Pfizer, Roche, Clovis, and GSK. PW receives honoraria as an advisory board member for Amgen, AstraZeneca, MSD, Novartis, Pfizer, Lilly, Roche, Teva, Eisai, Gilead, GSK, and Daiichi Sankyo. OO works in a certified breast cancer center, gynecologic cancer center, and oncologic center. OO is a member of the Executive Board of the German Cancer Society, head of the University Cancer Center Regensburg, and a member of the Board of Directors of CCC WERA. TL works in a certified breast and gynecologic cancer center. TP is head of a DKG-certified breast and gynecologic cancer center. St. Marien Amberg Medical Center is also an oncology center according to the criteria of the DKG. TL honoria: Amgen, Roche, Teva, Clovis, Tesaro, MSD, Novartis, Pfizer, Lilly, GSK, Gilead, Astra Zeneca, Daiichi Sankyo, Stemline, and Seagen; TL advisory boards: Amgen, MSD, Tesaro, Roche, Pfizer, Lilly, Myriad, Esai, GSK, Gilead, Daiichi Sankyo, Roche, Astra Zeneca; TL Travel Support: Pfizer, Pharma mar, MSD, Celgene, Roche, Astra Zeneca, Gilead, Daiichi Sankyo, and Stemline. All other authors have no relevant financial or non-financial interests to disclose. The design and interpretation were carried out independently and no interest group was able to influence them.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}